Shares of Biogen Inc. BIIB slipped 5.90% to $113.38 Thursday, on what proved to be an all-around rough trading session for ...

Shares of Biogen Inc. BIIB slipped 4.31% to $114.05 Tuesday, on what proved to be an all-around poor trading session for the ...

Organon (OGN) announced that it has acquired from Biogen (BIIB) regulatory and commercial rights in the U.S. for Tofidence, a biosimilar to ...

Biogen signs lease for Kendall Common as part of multi-year real estate optimization plan to modernize its facilities and consolidate its Massachusetts real estate footprint New building will be ...

Morgan Stanley lowered the firm’s price target on Biogen (BIIB) to $152 from $157 and keeps an Equal Weight rating on the shares. The firm ...

Biogen briefly moved its headquarters out to Weston, a town 30 minutes from Kendall Square, in 2010 before quickly announcing it would move back to Cambridge a year later.

Shout! Studios, the multi-platform media company backed by Oaktree Capital Management, has acquired Gravitas Ventures from Anthem Sports & Entertainment, Inc. The deal was finalized over the ...

Happy to be moderating my annual panel where Priya has to listen to me pepper her with questions for 40 minutes or so with Priya Singhal, Head of Development at Biogen. Thank you, Priya for ...

The multi-platform media company backed by Oaktree Capital Management, has acquired Gravitas Ventures from Anthem Sports & Entertainment, Inc. According to the official release, the addition to Shout!

Organon acquired regulatory and commercial rights in the United States for TOFIDENCE ™, a biosimilar to ACTEMRA ®, for intravenous infusion from Biogen. TOFIDENCE, the first approved ...

The acquisition gives Shout! access to Gravitas Ventures’ library of 3,300 scripted, non-scripted, and sports-related feature film, documentary, and TV titles, and it means that Shout!

The two companies have been partnered on Samsung Bioepis for the best part of a decade, successfully bringing six biosimilar copies of biologic drugs to regulatory approval, but Biogen now says it ...